Insider Selling Signals a Strategic Shift at Tempus AI
Recent filings reveal that CEO Thomas Schoenherr has sold 10,281 Class A shares on 25 September 2026, a move that follows a string of sales during August. The sale, executed under a Rule 10b‑5‑1 trading plan, came at a price of $85—slightly below the closing price of $85.08 on 27 September—indicating a modest discount to the market. With a market cap of $15.34 billion and a trailing P/E of –31.05, Tempus AI remains a high‑growth, negative‑earnings play; insiders selling may be viewed by investors as a signal that the company’s prospects are less bullish than the current market sentiment, which has been highly amplified (buzz ≈ 118 %) but only marginally positive (+76).
What Does This Mean for Investors? The pattern of frequent insider sales, coupled with the fact that Schoenherr’s holdings have steadily fallen from over 107 k shares in May to just 76.7 k today, suggests that the CEO is cashing out of his restricted‑stock unit (RSU) pool. Unlike the large, one‑off sales by the founder/Chairman Eric LeFokosy, these smaller, systematic moves are consistent with a disciplined trading plan rather than a reaction to impending negative news. Nonetheless, the cumulative sales of more than 30 k shares in August and early September raise a question about the company’s ability to sustain momentum in a market that has already seen a 31 % monthly rise but a 6 % yearly decline. For investors, this could translate into a short‑term price pullback or, conversely, an opportunity to buy before the company’s valuation normalizes.
A Profile of Thomas Schoenherr Thomas Schoenherr, the Diagnostics chief, has a history of opportunistic yet orderly sales. In August alone he executed six trades ranging from 500 to 3,094 shares, averaging around $56 per share—below the intraday highs that season. His purchases in late August (2,694 shares at $70) and early September (10,281 shares at $85) show a willingness to buy when the price dips, yet his subsequent sell on 25 September suggests a focus on liquidity rather than speculation. This pattern aligns with a professional who uses a pre‑arranged Rule 10b‑5‑1 plan to manage RSU vesting schedules, a common practice among high‑level executives in high‑growth tech and biotech firms. The fact that his holdings still remain in the high‑70 k range indicates that he retains a significant stake, which may continue to support the stock if the company delivers on its AI‑driven diagnostics roadmap.
Looking Ahead The company’s fundamentals—particularly its negative P/E and lack of earnings—remain a hurdle, but the surge in social‑media buzz indicates that investors are still watching the AI diagnostics space closely. If Tempus AI can translate its technology into early revenue or strategic partnerships, the insider selling may be viewed as a prudent liquidity move rather than a red flag. Short‑term traders should monitor the stock’s volatility around major data releases, while longer‑term investors can assess whether the CEO’s remaining stake and the company’s market cap justify a position in an AI‑driven healthcare leader that has already peaked near a 52‑week high of $104.32.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-09-25 | Schoenherr Thomas Edward (CEO, Diagnostics) | Sell | 10,281.00 | 85.00 | Class A Common Stock |
